Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

NCT02989714 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Interleukin-2
DRUG: Nivolumab

Sponsor

University of Michigan Rogel Cancer Center